108719-40-0

Usage

Uses

Used in Pharmaceutical Industry:
2,4-DIPHENYL-2H-PYRAZOL-3-YLAMINE is used as a chemical intermediate for the synthesis of various pharmaceuticals, contributing to the development of new drugs and therapeutic agents.
Used in Dye and Pigment Industry:
In the dye and pigment industry, 2,4-DIPHENYL-2H-PYRAZOL-3-YLAMINE is used as a key intermediate in the production of dyes and pigments, enhancing the color properties and stability of these products.
Used in Organic Compounds Synthesis:
2,4-DIPHENYL-2H-PYRAZOL-3-YLAMINE is utilized as a building block in the synthesis of various organic compounds, playing a crucial role in the creation of complex organic molecules for different applications.
Used in Anti-Inflammatory Applications:
Although research is ongoing, 2,4-DIPHENYL-2H-PYRAZOL-3-YLAMINE is being explored as a potential anti-inflammatory agent, suggesting its use in the development of treatments for inflammatory conditions.
Used in Anti-Cancer Applications:
Preliminary studies have indicated the potential of 2,4-DIPHENYL-2H-PYRAZOL-3-YLAMINE as an anti-cancer agent, and it is being investigated for its possible role in cancer treatment, with further research needed to confirm its efficacy and safety.

Upstream product

• 5841-70-3 phenyl(formyl)acetonitrile 
• 100-63-0 phenylhydrazine 
• 62914-60-7 (E)-3-hydroxy-2-phenylacrylonitrile 
• 140-29-4 phenylacetonitrile 
• 1076197-29-9 5-amino-1,4-diphenyl-1H-pyrazole-3-carboxylic acid 

Relevant academic research and scientific papers

HETEROCYCLE SUBSTITUTED AMINO-PYRIDINE COMPOUNDS AND METHODS OF USE THEREOF

The present disclosure relates to heterocycle substituted amino-pyridine compounds. The present disclosure also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present disclosure also relates to the use of such compounds for research or other non-therapeutic purposes.

Substituent effects of N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamides on positive allosteric modulation of the metabotropic glutamate-5 receptor in rat cortical astrocytes

CDPPB [3-cyano-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide] was recently described as the first centrally active, positive allosteric modulator of rat and human metabotropic glutamate receptor (mGluR) mGluR5 subtype. We explored the structural requirements for potentiation of glutamate-induced calcium release in naturally expressed mGluR5 in cultured rat astrocytes and increasing affinity for the allosteric antagonist binding site by evaluating 50 analogues of CDPPB. In the fluorometric calcium assay, CDPPB exhibited an EC50 value of 77 ± 15 nM in potentiating mGluR 5-mediated responses in cortical astrocytes and a Ki value of 3760 ± 430 nM in displacing [3H]methoxyPEPy binding in membranes of cultured HEK-293 cells expressing rat mGluR5. The structure-activity relationships showed that electronegative aromatic substituents in the para-position of the benzamide moiety of CDPPB increase potency. Both binding and functional activities were further increased with a halogen atom in the ortho-position of the 1-phenyl ring. These effects of substitution do not match those of either aromatic ring of MPEP [2-methyl-6-(phenylethynyl)-pyridine] for the antagonist allosteric binding site. Combination of the optimal substituents and aromatic positions resulted in 4-nitro-N-(1-(2-fluorophenyl)-3-phenyl-1H-pyrazol-5-yl)benzamide (VU-1545) showing Ki = 156 ± 29 nM and EC50 = 9.6 ± 1.9 nM in the binding and functional assays, respectively.